Abiraterone in metastatic prostate cancer without previous chemotherapy (Q24612084)

Dana E Rathkopf

33

0 references

Joan Carles Galcerán

Joan Carles

11

0 references

Ethan Basch

13

Ethan Basch

0 references

Karim Fizazi

7

Karim Fizazi

0 references

Mary-Ellen Taplin

28

Mary-Ellen Taplin

0 references

Marc Colombel

1 reference

ORCID Public Data File 2021

Fred Saad

15

Fred Saad

0 references

author name string

Charles J Ryan

1

0 references

Matthew R Smith

2

0 references

Johann S de Bono

3

0 references

Arturo Molina

4

0 references

Christopher J Logothetis

5

0 references

Paul de Souza

6

0 references

Paul Mainwaring

8

0 references

Siobhan Ng

10

0 references

Peter F A Mulders

12

0 references

Eric J Small

14

0 references

Dirk Schrijvers

16

0 references

Hendrik Van Poppel

17

0 references

Som D Mukherjee

18

0 references

Henrik Suttmann

19

0 references

Winald R Gerritsen

20

0 references

Thomas W Flaig

21

0 references

Daniel J George

22

0 references

Evan Y Yu

23

0 references

Eleni Efstathiou

24

0 references

Allan Pantuck

25

0 references

Eric Winquist

26

0 references

Celestia S Higano

27

0 references

Youn Park

29

0 references

Thian Kheoh

30

0 references

Thomas Griffin

31

0 references

Howard I Scher

The New England Journal of Medicine

32

0 references

language of work or name

English

0 references

publication date

10 January 2013

0 references

published in

0 references

volume

368

0 references

page(s)

138-48

0 references

issue

2

0 references

cites work

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Abiraterone and increased survival in metastatic prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Castration-resistant prostate cancer: many treatments, many options, many challenges ahead

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

A perspective on surrogate endpoints in controlled clinical trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683570

The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23228172

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A population-based study of prostate cancer chemotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23228172

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23228172